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ABSTRACT  
 
Purpose: Systemic inflammation often leads to complications in critically ill patients. Activation of the receptor 
for advanced glycation end-products (RAGE) generates inflammatory cytokines, proteases and oxidative stress 
and may link inflammation to subsequent organ damage. Furthermore, hyperglycemia-induced oxidative stress 
increases RAGE ligands and RAGE expression. We hypothesized that preventing hyperglycemia during critical 
illness reduces the risk of excessively enhanced RAGE signaling which could relate to clinical outcomes and risk 
of death.  
 
Methods: In 405 long-stay surgical ICU patients randomized to intensive or conventional insulin treatment, 
serum concentrations of soluble RAGE (decoy receptor) and the RAGE ligands high-mobility group box 1 
(HMGB1) and S100A12 were measured on admission, day 7 and last day. These were compared with levels in 
71 matched control subjects and with C-reactive protein (CRP) as routinely monitored inflammation marker. 
 
Results: Upon admission, soluble RAGE, HMGB1, S100A12 and CRP were higher in patients than in controls. 
HMGB1, S100A12 and CRP remained elevated throughout ICU stay, whereas soluble RAGE decreased to levels 
lower than in controls by day 7. Unexpectedly, insulin treatment did not affect the circulating levels of these 
markers. In univariable analysis, elevated levels of soluble RAGE upon admission were associated with adverse 
outcome, including circulatory failure, kidney failure, liver dysfunction and mortality. The associations with 
circulatory and kidney failure remained significant in multivariable logistic regression analysis corrected for 
baseline risk factors.  
 
Conclusions: Critical illness affects components of RAGE signaling, unaffected by insulin treatment. Elevated 
upon-admission soluble RAGE was associated with adverse outcomes.  
 
 
KEYWORDS 
 
Critical illness, inflammation, RAGE, sRAGE, HMGB1, S100A12 
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INTRODUCTION 
 
Persistent systemic inflammation caused by infectious and non-infectious (trauma and surgery) conditions is 
frequently associated with immune suppression and catabolism and may ultimately lead to organ damage, 
neuromuscular weakness, prolonged dependency on intensive care and death [1]. The receptor for advanced 
glycation end-products (RAGE) has been identified as an important mediator amplifying and perpetuating 
inflammation, linking inflammation to subsequent organ damage and adverse outcome in e.g. sepsis, acute lung 
injury and myocardial dysfunction [2].  
Engagement of membrane-bound RAGE activates several signaling pathways that regulate processes of 
inflammation, apoptosis, proliferation and autophagy. Among them, activation of the nuclear factor-kappa B 
(NF-kB)-pathway generates a wide array of inflammatory cytokines, chemokines, adhesion molecules and 
proteases, and increases the oxidative stress burden. Moreover, NF-kB activation leads to receptor up-regulation, 
which ensures perpetuation and amplification of the signal [3]. 
RAGE recognizes different ligands through their three-dimensional structure and has therefore been considered a 
pattern recognition receptor [3]. Putative ligands comprise advanced glycation end-products (AGEs), high-
mobility group box 1 (HMGB1), S100 proteins, amyloid-ß-peptide and ß-fibrils [3]. Different soluble RAGE 
forms exist, probably acting as decoy receptor by binding the same ligands and thus conferring protection against 
overwhelming inflammation. sRAGE is a truncated form of RAGE, which under inflammatory conditions is 
cleaved from the full-length receptor by A-disintegrin and metalloprotease 10 (ADAM10) [4]. Endogenous 
secreted RAGE (esRAGE) is produced by alternative mRNA splicing [5]. The nuclear DNA-binding protein 
HMGB1 is actively secreted by activated inflammatory cells or passively released by necrotic cells in areas of 
tissue damage. Extracellular functions relate to neurite outgrowth, cell migration, chemotaxis and tumor cell 
metastasis, dendritic cell maturation and activation of innate immune cells to release pro-inflammatory 
mediators. HMGB1 binds, amongst others, to RAGE, thus activating NF-kB and mitogen-activated protein 
kinase pathways [6]. HMGB1 has been described as a late mediator of sustained systemic inflammation in 
models of endotoxemia, peritonitis by cecal ligation and puncture and hemorrhagic shock [7, 8]. S100A12 is an 
intracellular calcium binding protein of the S100 family which is important in cell homeostasis. Upon cell 
damage, infectious or inflammatory signals, S100A12 is released from activated neutrophils into the 
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extracellular compartment and acts as a pro-inflammatory danger signal. Subsequent engagement of RAGE was 
demonstrated in e.g. processes of wound healing, tumor growth and inflammation [9]. 
Soluble RAGE (hereafter for convenience denoted as sRAGE) and RAGE-ligands have been evaluated as 
biomarkers of sustained or overwhelming inflammation predicting outcome in small studies on selected acute 
conditions as sepsis, acute respiratory distress syndrome (ARDS) and pneumonia [10, 11]. They have also been 
related to prognosis, development of complications and guiding of therapy in chronic inflammatory and auto-
immune diseases, such as coronary artery disease, rheumatoid arthritis and diabetes [12]. In particular, in 
diabetes hyperglycemia-induced acceleration of RAGE ligand production has been related to RAGE activation, 
increased production of reactive oxygen species (ROS) and diabetic complications, whereas RAGE ligands and 
soluble RAGE are modulated with glycemic control [13, 14]. 
In this study, we quantified the circulating levels of sRAGE, HMGB1 and S100A12 at different time points in a 
large heterogeneous group of long-stay critically ill patients. In view of the common development of 
hyperglycemia in critical illness and the highlighted diabetes literature, we hypothesized that maintaining 
normoglycemia with intensive insulin therapy (IIT) during ICU stay [15] would attenuate the levels of HMGB1 
and S100A12 while increasing sRAGE levels. As mentioned, data on the levels of these markers were only 
available from small, selected subgroups of critically ill patients. Therefore, we also performed a detailed 
assessment of whether admission levels of these proteins in a large heterogeneous patient population are 
associated with baseline characteristics of the patients or clinical complications. Baseline characteristics included 
type of surgery, sepsis upon admission, medical history, body mass index and age. The acquisition of a 
bloodstream infection, development of organ dysfunction (circulatory failure, kidney and liver dysfunction) and 
mortality were studied as clinical outcome variables. In addition, we systematically compared the performance 
of these markers with C-reactive protein (CRP) as a routinely measured inflammation marker.  
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MATERIALS AND METHODS 
 
Subjects 
This study is a pre-planned subanalysis of patients enrolled in a large prospective, randomized, controlled study 
on the effects of maintaining normoglycemia with intensive insulin therapy on outcome in a university hospital 
surgical intensive care unit [15]. In brief, strict glycemic control (80-110 mg/dl) with continuous infusion of 
insulin (intensive insulin therapy, IIT) was compared with treating stress hyperglycemia only when exceeding 
215 mg/dl and stopping insulin infusion when levels dropped below 180 mg/dl (conventional insulin therapy, 
CIT). All patients requiring at least 7 days of intensive care (n=405) were included in this analysis (Table 1). We 
included 71 healthy individuals as a control group, matched with the patients for age (65 [55-73] years, P=0.4), 
gender (69% male, P=0.8) and BMI (25.5 [23.3-27.3] kg/m2, P=0.8). 
Written informed consent was obtained from the volunteers, the patients or their next-of-kin. The study protocol, 
as well as the consent forms, were approved by the KU Leuven Institutional Review Board (ML1094, ML2707). 
The study was performed in accordance with the Declaration of Helsinki.  
 
Blood sampling and biochemical analyses 
Blood glucose and plasma CRP, creatinine, and bilirubin were determined with routine clinical chemistry assays 
during the clinical study. Additional blood samples were taken upon admission and daily at 6.00 a.m. until 
discharge or death. After centrifugation, serum was kept frozen at -80°C until analysis. We determined the 
concentration of sRAGE, HMGB1 and S100A12 in serum harvested upon admission, day 7 and last day in ICU, 
using commercial enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer’s 
instructions (Quantikine Human RAGE Immunoassay, R&D Systems, Abingdon, UK; HMGB1 ELISA, IBL, 
Hamburg, Germany; CircuLex S100A12/EN-RAGE ELISA kit, MBL International Corporation, Woburn, MA).  
 
Statistical analysis 
We used StatView 5.0.1 (SAS Institute Inc., Cary, NC) for statistical analyses. Data are presented as medians 
and interquartile ranges or as proportions and percentages. Continuous variables were analyzed with Mann-
Whitney U and proportions with the chi-square test. Associations between variables were calculated with 
Spearman’s correlation coefficient. Multivariable regression analysis was performed to further assess the 
significant associations of baseline levels of sRAGE, HMGB1 and S100A12 with ICU outcomes (acquisition of 
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a bloodstream infection, circulatory failure, kidney dysfunction, liver dysfunction and mortality) while correcting 
for baseline risk factors. Known classical baseline characteristics and risk factors (history of diabetes or 
malignancy, severity of illness, admission diagnosis, sepsis upon admission) as well as baseline CRP, as 
routinely measured inflammation marker, were considered, together with serum levels upon-admission of 
sRAGE, HMGB1 and S10012, entered either separately or combined. Area under the receiver-operating 
characteristic (ROC) curves (AUC) for baseline levels of sRAGE, HMGB1, S100A12 and CRP in the prediction 
of outcome were calculated with JMP10.0.0 (SAS). Two-sided P values below 0.05 were considered significant. 
Sample numbers provided 100% statistical power to demonstrate a 50% increase in sRAGE and HMGB1 upon 
admission to the ICU as compared with healthy controls and a 25% change by IIT as compared with CIT [16].  
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RESULTS 
 
sRAGE, HMGB1, S100A12 and CRP in critically ill patients versus healthy controls 
Upon admission in ICU, serum sRAGE, HMGB1, S100A12 and CRP were elevated as compared to healthy 
control levels (Table 2). sRAGE decreased to levels lower than those seen in healthy volunteers by day 7 and 
remained low on the last day in ICU (Figure 1). HMGB1, S100A12 and CRP also decreased during ICU stay, 
but always remained higher than healthy control levels.  
 
Impact of intensive insulin therapy on sRAGE, HMGB1, S100A12 and CRP 
Admission serum concentrations of sRAGE, HMGB1, S100A12 and CRP were comparable for the CIT and IIT 
groups (Figure 2). IIT did not affect circulating levels of these proteins at day 7 or last day in ICU (Figure 2), 
irrespective of having pre-existing diabetes or not (data not shown), but lowered CRP. 
 
Association of baseline sRAGE, HMGB1, S100A12 and CRP with baseline characteristics 
Cardiac surgery patients had similar sRAGE, but lower HMGB1, S100A12 and CRP levels upon ICU admission 
as compared with patients undergoing another type of surgery (Figure 3). HMGB1 and S10012 remained lower 
in cardiac surgery patients on day 7, but were comparable on the last day in ICU. In contrast, sRAGE levels on 
day 7 and last day and CRP levels on the last day were higher in cardiac surgery than in non-cardiac surgery 
patients. Patients with sepsis upon admission had higher upon-admission HMGB1, S100A12 and CRP levels 
than those without, but comparable sRAGE (Figure 3). sRAGE on day 7 and last day, as well as last day CRP 
were lower in patients with sepsis.  
A history of diabetes did not affect the levels of these proteins, except that HMGB1 levels on day 7 were higher 
than in patients without previously diagnosed diabetes (data not shown). sRAGE was significantly lower in 
patients with a history of malignancy upon admission (1472 [763-2730] pg/ml) than in those without (1963 
[1147-3151] pg/ml, P=0.02). This difference was maintained at the later time points. None of the proteins were 
significantly associated with age or obesity (data not shown). There was no association between baseline 
sRAGE, HMGB1, S100A12 and CRP (data not shown).  
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Association of baseline sRAGE, HMGB1, S100A12 and CRP with infection, organ dysfunction and outcome 
In univariable analysis, upon admission serum concentrations of sRAGE, HMGB1, S100A12 and CRP, or the 
time courses of these analytes, were not associated with subsequent acquisition of bacteremia (Figure 4). In 
contrast, admission sRAGE levels were higher in patients with circulatory failure defined as need of vasoactive 
support (1.96 [1.12-3.24] ng/ml ) versus those without (1.42 [0.79-2.59] ng/ml, P=0.006). Admission sRAGE 
levels were also higher in patients who developed acute kidney injury, reflected by a peak creatinine exceeding 
2.5 mg/dl (2.06 [1.35-2.98] ng/ml versus 1.76 [0.97-3.04] ng/ml, P=0.04) and by the need for renal replacement 
therapy (2.38 [1.50-3.47] ng/ml versus 1.71 [0.97-2.87] ng/ml, P=0.002) (Figure 4). Likewise, admission 
sRAGE was significantly elevated in patients who subsequently developed cholestatic liver dysfunction defined 
by a peak bilirubin ≥2 mg/dl (2.11 [1.23-3.47] ng/ml) versus patients with a lower peak bilirubin (1.55 [0.93-
2.62] ng/ml, P=0.001) (Figure 4). Elevated admission sRAGE was also associated with hospital mortality (2.11 
[1.43-3.52] ng/ml in non-survivors versus 1.80 [0.98-2.85] ng/ml in survivors, P=0.03). For renal replacement 
therapy and hospital mortality, these associations were still present on day 7 and last day in ICU (Figure 4). 
Association of outcomes with the other inflammation markers upon ICU admission were limited to lower 
HMGB1 levels in patients who died in the hospital (4.84 [3.10-8.40] ng/ml in non-survivors versus 6.50 [3.48-
11.19] ng/ml in survivors, P=0.02), and higher S100A12 levels in patients developing circulatory failure (0.68 
[0.27-1.67] ng/ml versus 0.40 [0.13-1.16] ng/ml, P=0.01) or cholestatic liver dysfunction (0.79 [0.27-1.81] 
µg/ml versus 0.48 [0.18-1.32] µg/ml, P=0.01). These associations were less preserved throughout ICU stay. CRP 
levels on day 7 and last day in ICU were higher in patients who needed renal replacement therapy, in patients 
who developed cholestatic liver dysfunction and in patients who died in the hospital (Figure 4). 
In multivariable regression analysis, correcting for baseline characteristics and risk factors (history of diabetes or 
malignancy, APACHE-II, type of critical insult and sepsis upon admission) as well as baseline CRP, elevated 
admission sRAGE was still associated with circulatory failure and need for renal replacement therapy (Table 3). 
Adding the admission values for HMGB1 and S100A12 to the model, sRAGE remained independently 
associated with need for renal replacement therapy. Interestingly, when the three inflammation markers were 
added to the model, S100A12 appeared independently associated with cholestatic liver dysfunction and HMGB1 
with hospital mortality.  
Nevertheless, ROC curve analysis showed poor predictive value of the markers in relation to outcome (data not 
shown). 
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DISCUSSION  
 
We demonstrated that the decoy receptor sRAGE and the RAGE ligands HMGB1 and S100A12 are elevated in a 
large heterogeneous cohort of prolonged critically ill patients upon admission to ICU. sRAGE levels decreased 
below healthy control levels by day 7 and remained low until the last ICU day, whereas HMGB1 and S100A12 
remained elevated. Maintenance of normal blood glucose levels with insulin unexpectedly did not affect the 
levels of these markers. Admission levels of sRAGE in particular were associated with subsequent organ 
dysfunction (circulatory dysfunction, need for renal replacement therapy and cholestatic liver dysfunction) and 
hospital mortality. These associations remained significant for circulatory and kidney failure after correction for 
baseline risk factors and severity of illness.  
 
The elevated levels of sRAGE, HMGB1 and S100A12 upon ICU admission are in line with several studies in 
mostly small cohorts of critically ill patients, mostly with a selected pathology [10, 11, 17]. Interestingly, 
whereas admission sRAGE levels were elevated, the levels of sRAGE fell below the level of healthy volunteers 
at the later time points in ICU. This may reflect an acute peak induced by massive inflammation that induces a 
proteolytic environment and mediates receptor shedding, which is then followed by a sustained decrease that 
occurs when the condition becomes more chronic. The latter would thus reflect an exhausted protective anti-
inflammatory system. Indeed, sRAGE probably acts as a decoy receptor by binding the RAGE ligands and may 
thus confer a protective mechanism against overwhelming inflammation. Decreased soluble RAGE levels have 
been reported in chronic conditions in which RAGE ligands accumulate, such as diabetes, atherosclerosis and 
rheumatoid arthritis, and where low levels of the soluble receptor are associated with more severe disease and 
worse outcome [18].  
 
Critical illness is associated with inflammation and increased oxidative stress, contributing to organ failure and 
mortality. Binding of ligands to RAGE increases oxidative stress. In diabetes, hyperglycemia precipitates the 
pro-oxidant state, whereas glucose control is able to down-regulate RAGE signaling and the oxidative burden 
[13, 14, 19]. Several studies in patients with diabetes have indeed highlighted the association between glycemic 
control and level of sRAGE, RAGE ligands, markers of oxidative stress and diabetic complications. We 
previously demonstrated inhibition of excessive iNOS-induced NO release, possibly via reduced NF-kB-
activation, in patients with prolonged critical illness [19] as well as reduced oxidative stress in critically ill 
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animals [20] with strict glycemic control. Thus, it was rather unexpected that the intervention did not affect 
circulating levels of sRAGE, HMGB1 or S100A12. Recent findings in a small cohort suggested a decrease of 
sRAGE by insulin therapy in critically ill patients with diabetes, but not in those without [16]. In our study, 
however, IIT failed to affect sRAGE irrespective of pre-existing diabetes.  
 
Elevated sRAGE and S100A12 levels upon ICU admission correlated with the need for hemodynamic support. 
So far, this association has not been described. Interestingly though, inflammation induced by activation of the 
RAGE axis has been linked to subsequent myocardial and vascular dysfunction [21, 22].  
 
sRAGE levels upon ICU admission were higher in patients who subsequently developed new kidney injury than 
in those who did not, whereas no such relation was found for the other markers. sRAGE was associated with new 
kidney injury independent of baseline risk factors and of the routinely measured inflammation marker CRP and 
the other studied markers. After severe trauma, a significant relationship has been observed between sRAGE and 
development of acute renal failure [23]. In patients with septic acute kidney injury, the kidney is regarded both 
culprit and target of RAGE signaling [24]. Actually, elevated levels of AGEs and sRAGE, accumulating due to 
impaired clearance as in chronic kidney disease [12, 25], lead to further activation and shedding of RAGE from 
the renal (mesangial) cells [24]. In our study, the acute increase in sRAGE is more likely to reflect the 
inflammatory burden as the vast majority of patients had no impairment of renal function prior to admission. 
Whereas we did not find any association of HMGB1 with acute kidney injury, HMGB1 is released from renal 
cells into the circulation after ischemia-reperfusion injury, inducing pro-inflammatory cytokine production. 
Neutralizing HMGB1 with antibodies or inhibiting its release reduced ischemic damage [26]. Data on S100A12 
in relation to acute kidney injury are not available, but levels are known to be elevated in chronic kidney injury 
requiring hemodialysis [27]. Overall, accumulation of RAGE ligands, inducing RAGE up-regulation, has been 
proposed to contribute to both diabetic and non-diabetic nephropathy [13, 14]. 
 
Elevated sRAGE was also associated with the development of cholestatic liver dysfunction. Since the liver 
represents the major site of AGE metabolism, it is conceivable that impaired hepatic function might result in 
elevated levels of AGEs with subsequent RAGE activation. Moreover, high levels of RAGE expression are 
commonly observed in the biliary system [28], pointing at its potential role in the disposition of AGEs. The 
hepatocytes seem to be most vulnerable to the detrimental effects of AGEs [28]. Decreased sRAGE levels have 
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been described in liver steatosis [29], non-alcoholic fatty liver disease [30] and intrahepatic cholestasis of 
pregnancy [31]. These data support a role for sRAGE as decoy receptor and exhaustion of this defense 
mechanism in chronic conditions. No data are available on association of HMGB1 or S100A12 with cholestatic 
liver dysfunction of critical illness. 
 
The association of elevated admission sRAGE and subsequent mortality is consistent with several previous 
studies. Thus, sRAGE predicted mortality in critically ill patients with sepsis, acute lung injury/ARDS and 
trauma [11, 21, 32], although not all studies found such association [16]. Whereas HMGB1 has been identified 
as a late mediator of sepsis-induced lethality in animal models, we observed lower HMGB1 levels upon ICU 
admission in patients who would not survive than in survivors. This counterintuitive finding has also been 
observed in patients with sepsis [33]. In contrast, elevated baseline HMGB1 predicted mortality in patients with 
pneumonia-related ARDS [34]. S100A12 has been linked to mortality and adverse outcome in patients with 
chronic renal failure and chronic cardiovascular disease [9, 27, 35], but data in critical illness are lacking.  
 
In our study, elevated sRAGE was associated with organ dysfunction and death. However, caution is warranted 
regarding technical aspects of the assay used to quantify these levels. Several forms of soluble RAGE exist 
which may bind different ligands, whereas commercial ELISAs used in our study and most of the cited studies 
do not discriminate between these forms. Endogenous secreted RAGE (esRAGE) is produced by alternative 
mRNA splicing [5] and is regarded an endogenous anti-inflammatory decoy receptor, protecting from excessive 
inflammation by binding and scavenging potential ligands for RAGE. As such, elevated levels are believed to 
reflect an adequate, protective pathway. This may explain why elevated soluble RAGE levels are observed in 
extreme longevity, whereas decreased levels are associated with chronic (auto)immune and inflammatory 
diseases [12]. Another form, as mentioned, is released from the cell surface receptor under inflammatory 
conditions by ADAM10-mediated proteolytic cleavage and may represent (acute) RAGE activation and cellular 
damage, where the protective effects as decoy receptor are overwhelmed in a self-amplifying loop [4, 12]. 
Soluble RAGE levels measured in the present study may therefore reflect expression of the truncated receptor 
itself, the local proteolytic environment, or both. The source remains to be elucidated. In addition, this study 
merely established assocations with outcome, but does not prove causality.  
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Conclusions 
Critically ill patients show increased levels of soluble RAGE, HMGB1 and S100A12 upon ICU admission, 
likely reflecting massive inflammation. Soluble RAGE levels subsequently decreased below healthy control 
levels, which may reflect exhaustion of the protective anti-inflammatory system the decoy receptor provides, 
whereas HMGB1 and S100A12 remained elevated until the last day in ICU. Strict glycemic control during ICU 
stay had no impact on the levels of these markers and hence, these markers are not involved in the beneficial 
effects of this intervention on clinical outcome. In particular admission levels of soluble RAGE were associated 
with development of organ failure and with hospital mortality. Nevertheless, performance in ROC curve analysis 
was poor, indicating that the studied markers are not generally suitable as circulating biomarker to predict 
outcome of critically ill patients. 
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APPENDIX 
 
LIST OF ABBREVIATIONS 
ADAM10: A disintegrin and metalloprotease 10, AGEs: advanced glycation end-products, APACHE-II: acute 
physiology and chronic health-II score, ARDS: acute respiratory distress syndrome, BMI: body mass index, CIT: 
conventional insulin therapy, CRP: C-reactive protein, ELISA: enzyme-linked immunosorbent assay, HMGB1: 
high-mobility group box 1, ICU: intensive care unit, IIT: intensive insulin therapy, NF-kB: nuclear factor kappa 
B, RAGE: receptor for advanced glycation end-products, ROS: reactive oxygen species, sRAGE: soluble RAGE. 
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Table 1: Baseline characteristics  
 
 Conventional 
insulin therapy 
n=224 
Intensive  
insulin therapy 
n=181 
P 
    
Sex (male, n (%) 150 (67) 125 (69) 0.7 
Age (yr, median [IQR]) 67 [52-74] 66 [53-73] 0.9 
BMI (kg/m2, median [IQR]) 24.9 [22.4-27.7] 25.4 [22.6-29.2] 0.3 
History of diabetes (n (%)) 21 (9) 18 (10) 0.8 
History of malignancy (n (%)) 50 (22) 42 (23) 0.8 
APACHE-II first 24h, median [IQR] 12 [8-15] 11 [8-16] 0.9 
TISS-28 score first 24h; median [IQR] 39 [33-45] 39 [35-45] 0.5 
Admission blood glucose (mg/dl, median [IQR]) 137 [115-165] 133 [109-163] 0.6 
 
BMI: body mass index; APACHE-II: Acute Physiology and Chronic Health Evaluation-II score; TISS-28: Therapeutic 
Interventions Scoring System-28. 
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Table 2: Admission levels of sRAGE, HMGB1 and S100A12 in critically ill patients and  healthy controls 
 
 ICU patients Healthy controls P 
    
sRAGE (pg/ml, median [IQR])  1897 [1056-3026] 1515 [1177-1948] 0.03 
HMGB1 (ng/ml, median [IQR]) 6.3 [3.4-10.4] 2.8 [2.0-5.2] <0.0001 
S100A12 (ng/ml, median [IQR]) 617 [234-1537] 112 [52-259] <0.0001 
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Table 3: Multivariable logistic regression analysis for RAGE-axis markers in relation to outcome 
 
Outcome variable Odds ratio (95% confidence interval) P 
   
Circulatory failure   
A.   sRAGE (per 100 pg/ml added) 1.017 (1.001-1.033) 0.03 
       HMGB1 (per ng/ml added) 1.017 (0.986-1.050) 0.28 
       S100A12 (per 100 ng/ml added) 1.032 (1.005-1.060) 0.01 
B.   sRAGE (per 100 pg/ml added) 1.015 (0.999-1.031) 0.06 
       HMGB1 (per ng/ml added) 1.005 (0.969-1.043) 0.79 
       S100A12 (per 100 ng/ml added) 1.027 (0.996-1.058) 0.08 
   
Renal replacement therapy   
A.   sRAGE (per 100 pg/ml added) 1.012 (1.000-1.024) 0.04 
       HMGB1 (per ng/ml added) 0.998 (0.971-1.025) 0.87 
       S100A12 (per 100 ng/ml added) 1.009 (0.985-1.033) 0.46 
B.   sRAGE (per 100 pg/ml added) 1.013 (1.001-1.025) 0.03 
       HMGB1 (per ng/ml added) 0.986 (0.955-1.019) 0.39 
       S100A12 (per 100 ng/ml added) 1.011 (0.984-1.038) 0.44 
   
Cholestatic liver dysfunction   
A.   sRAGE (per 100 pg/ml added) 1.010 (1.000-1.020) 0.06 
       HMGB1 (per ng/ml added) 0.992 (0.971-1.014) 0.48 
       S100A12 (per 100 ng/ml added) 1.016 (0.997-1.035) 0.10 
B.   sRAGE (per 100 pg/ml added) 1.009 (0.998-1.019) 0.10 
       HMGB1 (per ng/ml added) 0.979 (0.954-1.005) 0.10 
       S100A12 (per 100 ng/ml added) 1.024 (1.002-1.047) 0.03 
   
Hospital mortality   
A.   sRAGE (per 100 pg/ml added) 1.007 (0.995-1.018) 0.25 
       HMGB1 (per ng/ml added) 0.971 (0.939-1.004) 0.08 
       S100A12 (per 100 ng/ml added) 1.000 (0.977-1.023) 0.97 
B.   sRAGE (per 100 pg/ml added) 1.007 (0.995-1.019) 0.24 
       HMGB1 (per ng/ml added) 0.961 (0.925-0.999) 0.04 
       S100A12 (per 100 ng/ml added) 1.012 (0.986-1.040) 0.37 
   
 
Multivariable logistic regression models were built including the classical baseline risk factors history of 
diabetes, history of malignancy, cardiac versus non-cardiac surgery, severity of illness (APACHE-II score), 
sepsis upon admission, as well as CRP as classical marker of inflammation. The RAGE-axis markers were added 
to the model either separately (A) or all combined (B). 
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 FIGURE LEGENDS 
 
Fig 1. Levels of sRAGE, HMGB1, S100A12 and CRP during ICU stay  
Protein levels on admission, day 7 and last day of ICU stay are shown and are compared to the levels in healthy 
individuals (grey lines represent median and interquartile range). Data are expressed as boxplots, with the central 
lines indicating the median, the boxes the interquartile range and the whiskers the 10th and 90th percentile. P-
values were calculated with Mann-Whitney U. Numbers of patients available for analysis are indicated below the 
graphs. 
 
Fig 2. Effect of strict glycemic control with intensive insulin therapy on sRAGE, HMGB1, S100A12 and CRP.  
Protein levels on admission, day 7 and last day of ICU stay are compared for patients who received conventional 
(CIT) or intensive insulin therapy (IIT) during ICU stay. Data are presented as boxplots, with the central lines 
indicating the median, the boxes the interquartile range and the whiskers the 10th and 90th percentile. P-values 
were calculated with Mann-Whitney U. Numbers of patients available for analysis in each group are indicated 
below the graphs. 
 
Fig 3. Levels of sRAGE, HMGB1, S100A12 and CRP in relation to baseline characteristics  
Protein levels on admission, day 7 and last day of ICU stay are compared for patients with cardiac versus other 
surgery or having sepsis upon admission or not. Data are presented as boxplots, with the central lines indicating 
the median, the boxes the interquartile range and the whiskers the 10th and 90th percentile. P-values were 
calculated with Mann-Whitney U. Numbers of patients available for analysis in each group are indicated below 
the graphs. 
 
Fig 4. Levels of sRAGE, HMGB1, S100A12 and CRP in relation to clinical outcome 
Protein levels on admission, day 7 and last day of ICU stay are compared for patients with versus without 
bacteremia, circulatory failure, need for renal replacement therapy and cholestatic liver dysfunction as well as for 
patients who died in the hospital versus those who survived. Data are expressed as boxplots, with the central 
lines indicating the median, the boxes the interquartile range and the whiskers the 10th and 90th percentile. P-
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values were calculated with Mann-Whitney U. Numbers of patients available for analysis in each group are 
indicated below the graphs. 
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